Details

Autor(en) / Beteiligte

• Gu, Chunyin
• Cao, Xiaodan
• Wang, Zongda
• Hu, Xue
• Yao, Yanfeng
• Zhou, Yiwu
• Liu, Peipei
• Liu, Xiaowu
• Gao, Ge
• Hu, Xiao
• Zhang, Yecheng
• Chen, Zhen
• Gao, Li
• Peng, Yun
• Jia, Fangfang
• Shan, Chao
• Yu, Li
• Liu, Kunpeng
• Li, Nan
• Guo, Weiwei
• Jiang, Guoping
• Min, Juan
• Zhang, Jianjian
• Yang, Lu
• Shi, Meng
• Hou, Tianquan
• Li, Yanan
• Liang, Weichen
• Lu, Guoqiao
• Yang, Congyi
• Wang, Yuting
• Xia, Kaiwen
• Xiao, Zheng
• Xue, Jianhua
• Huang, Xueyi
• Chen, Xin
• Ma, Haixia
• Song, Donglin
• Pan, Zhongzong
• Wang, Xueping
• Guo, Haibing
• Liang, Hong
• Yuan, Zhiming
• Guan, Wuxiang
• Deng, Su-Jun

Titel

A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351

Ist Teil von

• mAbs, 2021, Vol.13 (1)

Ort / Verlag

Taylor & Francis

Erscheinungsjahr

2021

Link zum Volltext

Quelle

Taylor & Francis Journals Auto-Holdings Collection

Beschreibungen/Notizen

• Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease-2019 (COVID-19), interacts with the host cell receptor angiotensin-converting enzyme 2 (hACE2) via its spike 1 protein during infection. After the virus sequence was published, we identified two potent antibodies against the SARS-CoV-2 receptor binding domain (RBD) from antibody libraries using a phage-to-yeast (PtY) display platform in only 10 days. Our lead antibody JMB2002, now in a Phase 1 clinical trial (ChiCTR2100042150), showed broad-spectrum in vitro blocking activity against hACE2 binding to the RBD of multiple SARS-CoV-2 variants, including B.1.351 that was reportedly much more resistant to neutralization by convalescent plasma, vaccine sera and some clinical-stage neutralizing antibodies. Furthermore, JMB2002 has demonstrated complete prophylactic and potent therapeutic efficacy in a rhesus macaque disease model. Prophylactic and therapeutic countermeasure intervention of SARS-CoV-2 using JMB2002 would likely slow down the transmission of currently emerged SARS-CoV-2 variants and result in more efficient control of the COVID-19 pandemic.